Logo

Gen InCode: Paul Foulger

Dec 07, 2020

Gen InCode, an Oxford, UK-based company specializing in AI-powered genetic risk assessment for cardiovascular disease, has appointed Paul Foulger as CFO. Foulger previously served as group finance director at EKF Diagnostics, and is currently a non-executive director of Arcis Biotechnology and Autoclenz. He has also previously served as finance director at NovaBiotics, Elsevier Science, Venn Life Sciences, and PredictImmune, among other companies.

Breaking News
The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.